RxDoctor Payments Data

Jennifer Evans

Psychiatric/Mental Health · Michigan City, INNPI 1063781532

Payments from drug & device makers

$2,800in general payments, 2019–2025

Across 142 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$960
  • Alkermes, Inc.$451
  • Otsuka America Pharmaceutical, Inc.$272
  • Teva Pharmaceuticals USA, Inc.$234
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$186
  • Neurocrine Biosciences, Inc.$177
  • plus $520 from 11 others

What the payments were for

  • Food & beverage$2,74898%
  • Education$522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,800 in reported general payments places this provider in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$7,743
Medicare patients
22
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine17$108,900
Invega SustennaPaliperidone Palmitate28$99,714
VraylarCariprazine Hcl50$79,233
CaplytaLumateperone Tosylate27$47,854
Paliperidone ErPaliperidone39$9,115
Lurasidone Hcl36$4,880
Aripiprazole51$4,005
Bupropion XlBupropion Hcl29$3,859
Oxcarbazepine69$2,836
Divalproex Sodium ErDivalproex Sodium70$2,416
Hydroxyzine Hcl73$2,378
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$2,084
Fluphenazine Hcl20$2,026
Trazodone Hcl155$1,967
Methylphenidate ErMethylphenidate Hcl12$1,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$234$108,90017 claims
AbbVieVraylar$960$79,23350 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$186$47,85427 claims
Almatica Pharma LLCSertraline Hcl$30$1,178114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →